{"id":826215,"date":"2025-03-17T07:33:25","date_gmt":"2025-03-17T11:33:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/"},"modified":"2025-03-17T07:33:25","modified_gmt":"2025-03-17T11:33:25","slug":"aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/","title":{"rendered":"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance"},"content":{"rendered":"
\n

SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (\u201cAptose\u201d or the \u201cCompany\u201d) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) notifying the Company that it is in compliance with Nasdaq\u2019s minimum bid price requirement.<\/p>\n

On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company\u2019s common shares has been $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2). Separately, Aptose is not in compliance with the $2.5 million requirement and is operating under an exception granted by the Hearing Panel, which provides additional time to regain compliance, although there is no assurance that the Company will successfully achieve full compliance with the Nasdaq shareholders equity compliance requirements.<\/p>\n

\n About Aptose<\/strong>\n <\/p>\n

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company\u2019s lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.<\/p>\n

\n Forward Looking Statements <\/strong>\n <\/p>\n

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including statements relating to the Company\u2019s plans, objectives, expectations and intentions and other statements including words such as \u201ccontinue\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201cwould\u201d, \u201cmay\u201d, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to regain full compliance with Nasdaq listing requirements and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.<\/p>\n

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.<\/p>\n

For further information, please contact:<\/p>\n

\n Aptose Biosciences Inc.
<\/strong>Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (\u201cAptose\u201d or the \u201cCompany\u201d) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) notifying the Company that it is in compliance with Nasdaq\u2019s minimum bid price requirement. On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company\u2019s common shares has been $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2). Separately, Aptose is not … <\/p>\n

Continue reading “Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826215","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (\u201cAptose\u201d or the \u201cCompany\u201d) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) notifying the Company that it is in compliance with Nasdaq\u2019s minimum bid price requirement. On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company\u2019s common shares has been $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2). Separately, Aptose is not … Continue reading "Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-17T11:33:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance\",\"datePublished\":\"2025-03-17T11:33:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/\"},\"wordCount\":615,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/\",\"name\":\"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=\",\"datePublished\":\"2025-03-17T11:33:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/","og_locale":"en_US","og_type":"article","og_title":"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - Market Newsdesk","og_description":"SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (\u201cAptose\u201d or the \u201cCompany\u201d) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) notifying the Company that it is in compliance with Nasdaq\u2019s minimum bid price requirement. On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company\u2019s common shares has been $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2). Separately, Aptose is not … Continue reading \"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-17T11:33:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance","datePublished":"2025-03-17T11:33:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/"},"wordCount":615,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/","name":"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=","datePublished":"2025-03-17T11:33:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTI3OSM2ODA4NTE5IzIwMjcyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826215"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826215\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}